AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's CAPItello Phase 3 trial for Truqap (Capivasertib) combined with Paclitaxel in locally advanced/metastatic triple-negative breast cancer did not meet the dual primary endpoints of improvement in overall survival versus Paclitaxel plus placebo.
June 18, 2024 | 8:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca's CAPItello Phase 3 trial for Truqap (Capivasertib) in combination with Paclitaxel did not meet the primary endpoints for improving overall survival in advanced breast cancer patients.
The failure to meet the primary endpoints in a Phase 3 trial is a significant setback for AstraZeneca, as it impacts the potential marketability and revenue generation from Truqap (Capivasertib). This news is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100